Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Crowder

Interventional Cardiology Jackson, MS Medical Doctor

NPI 1619919479 CMS profile 345292

970 Lakeland Dr, Suite 61, Jackson, MS 39216

Open in the dashboard

General payments

$331,219

1,049 records reported · program years 2019–2025

Research payments

$12,935

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$87,945 paid to institutions, not to them · program years 2019–2025

Through program year 2025, William Crowder of Jackson, MS is reported in the CMS Open Payments database as having received $331,219 across 1,049 general payments and $12,935 in research payments paid to them. Separately, studies naming them as principal investigator received $87,945 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $48,240 104
2024 General $41,013 96
2023 General $75,009 146
2022 General $64,520 208
2021 General $30,057 170
2020 General $27,391 166
2020 Research $8,089 5
2019 General $44,988 159
2019 Research $4,846 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Crowder
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to William Crowder were reported at $48,240. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year William Crowder Interventional Cardiology median Middle half National median
2019 $44,988 $1,097 $329–$3,048 $163
2020 $27,391 $473 $161–$1,480 $114
2021 $30,057 $677 $233–$1,827 $132
2022 $64,520 $978 $333–$2,724 $149
2023 $75,009 $1,136 $382–$2,986 $160
2024 $41,013 $1,181 $395–$3,326 $164
2025 $48,240 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $156,187 151 payments
  2. E.R. Squibb & Sons, L.L.C. $52,566 40 payments
  3. Atricure, Inc. $29,897 35 payments
  4. Medtronic, Inc. $26,538 234 payments
  5. Shockwave Medical, Inc $16,733 26 payments
  6. Medtronic Vascular, Inc. $12,404 124 payments
  7. Siemens Medical Solutions USA, Inc. $8,500 17 payments
  8. Amgen Inc. $7,596 34 payments
  9. Abiomed $3,547 135 payments
  10. Abbott Laboratories $2,974 37 payments
  11. Other $14,277 216 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $133,842 49 payments
  2. Honoraria $55,980 12 payments
  3. Travel and Lodging $51,877 87 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $46,390 19 payments
  5. Food and Beverage $33,738 876 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $9,350 4 payments
  7. Education $42 2 payments
Products named General payments · program years 2019–2025
  1. GORE CARDIOFORM Septal Occluder $106,373 109 payments
  2. CARDIOFORM Septal Occluder $49,683 41 payments
  3. CAMZYOS $34,952 30 payments
  4. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $16,242 20 payments
  5. ATRICLIP LAA EXCLUSION SYSTEM $14,067 20 payments
  6. SYNERGY ABLATION SYSTEM $14,060 15 payments
  7. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $13,287 13 payments
  8. COREVALVE EVOLUT R $12,017 97 payments
  9. CoreValve Evolut $9,209 78 payments
  10. Repatha $7,571 32 payments
  11. Other $44,828 588 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Philips Electronics North America Corporation $12,935 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

4,864

Median for Interventional Cardiology: 2,236

Drug cost

$1,392,391

Median for Interventional Cardiology: $380,412

Branded share of claims

42%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Camzyos Mavacamten Brand 61 $490,710
Eliquis Apixaban Brand 350 $262,059
Entresto Sacubitril/Valsartan Brand 218 $202,635
Xarelto Rivaroxaban Brand 140 $133,230
Farxiga Dapagliflozin Propanediol Brand 115 $89,573
Repatha Sureclick Evolocumab Brand 70 $76,478
Brilinta Ticagrelor Brand 85 $38,048
Jardiance Empagliflozin Brand 43 $32,752
Praluent Pen Alirocumab Brand 18 $13,239
Multaq Dronedarone Hcl Brand 12 $9,723

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 107 billing codes

Paid by Medicare

$547,199

Of which drugs: $34,716

Medicare patients

1,714

Average age 75

Services billed

14,971

870 women, 844 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 54%
Diabetes 41%
Atrial fibrillation 31%
Chronic kidney disease 26%
Depression 26%
Heart failure 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 83 329 $1,672
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 58 5,279 $554

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
$6,412 61 —
JARDIANCE
$13 43 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,055 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record